The Valeda Light Delivery System, which uses multi-wavelength photobiomodulation (PBM), resulted in statistically significant improvements in visual acuity in patients with intermediate macular degeneration (AMD) compared to the simulator-treated group
Approximately 35% of PBM-treated eyes showed a clinically significant improvement in visual acuity by 5 or more letters after 9 months, indicating an overall improvement in visual function.
The study also found that PBM treatment prevented the formation of macular drusen (deposits) and the progression of advanced AMD.
PBM treatment was safe and well tolerated by study participants, even with the disruption in the form of the COVID-19 pandemic
The study showed that no safety problems or signs of eye damage were observed during the 10 months of the study.
In addition, according to research statistics, the patients reported a high degree of compliance with their scheduled clinic visits. This demonstrates that repeated photobiomodulation (PBM) treatment is effective for this group of patients.
